These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 9237497)
81. Predictive factors of the contracture test for diagnosing malignant hyperthermia in a Brazilian population sample: a retrospective observational study. de Mello JM; Andrade PV; Santos JM; Oliveira ASB; Vainzof M; do Amaral JLG; Almeida da Silva HC Braz J Anesthesiol; 2023; 73(2):145-152. PubMed ID: 35835312 [TBL] [Abstract][Full Text] [Related]
82. Evidence for a spontaneous C1840-T mutation in the RYR1 gene after DNA fingerprinting in a malignant hyperthermia susceptible family. Steinfath M; Seranski P; Singh S; Fiege M; Wappler F; Schulte Am Esch J; Scholz J Naunyn Schmiedebergs Arch Pharmacol; 2002 Oct; 366(4):372-5. PubMed ID: 12237752 [TBL] [Abstract][Full Text] [Related]
83. The role of CACNA1S in predisposition to malignant hyperthermia. Carpenter D; Ringrose C; Leo V; Morris A; Robinson RL; Halsall PJ; Hopkins PM; Shaw MA BMC Med Genet; 2009 Oct; 10():104. PubMed ID: 19825159 [TBL] [Abstract][Full Text] [Related]
84. Novel ryanodine receptor mutation that may cause malignant hyperthermia. Kaufmann A; Kraft B; Michalek-Sauberer A; Weigl LG Anesthesiology; 2008 Sep; 109(3):457-64. PubMed ID: 18719443 [TBL] [Abstract][Full Text] [Related]
85. The ryanodine contracture test may help diagnose susceptibility to malignant hyperthermia. Reuter DA; Anetseder M; Müller R; Roewer N; Hartung EJ Can J Anaesth; 2003; 50(7):643-8. PubMed ID: 12944436 [TBL] [Abstract][Full Text] [Related]
86. The differential effect of halothane and 1,2-dichlorohexafluorocyclobutane on in vitro muscle contractures of patients susceptible to malignant hyperthermia. Kindler CH; Girard T; Gong D; Urwyler A Anesth Analg; 2002 Apr; 94(4):1028-33, table of contents. PubMed ID: 11916818 [TBL] [Abstract][Full Text] [Related]
87. Malignant hyperthermia--a large kindred linked to the RYR1 gene. Wallace AJ; Wooldridge W; Kingston HM; Harrison MJ; Ellis FR; Ford PM Anaesthesia; 1996 Jan; 51(1):16-23. PubMed ID: 8669559 [TBL] [Abstract][Full Text] [Related]
88. Malignant hyperthermia and central core disease causative mutations in Swedish patients. Broman M; Islander G; Müller CR; Ranklev-Twetman E Acta Anaesthesiol Scand; 2007 Jan; 51(1):50-3. PubMed ID: 17081152 [TBL] [Abstract][Full Text] [Related]
90. Histological support for the difference between malignant hyperthermia susceptible (MHS), equivocal (MHE) and negative (MHN) muscle biopsies. Mezin P; Payen JF; Bosson JL; Brambilla E; Stieglitz P Br J Anaesth; 1997 Sep; 79(3):327-31. PubMed ID: 9389850 [TBL] [Abstract][Full Text] [Related]
91. DNA testing for malignant hyperthermia: the reality and the dream. Stowell KM Anesth Analg; 2014 Feb; 118(2):397-406. PubMed ID: 24445638 [TBL] [Abstract][Full Text] [Related]
92. Sources of variability in halothane and caffeine contracture tests for susceptibility to malignant hyperthermia. Ording H; Bendixen D Eur J Anaesthesiol; 1992 Sep; 9(5):367-76. PubMed ID: 1396623 [TBL] [Abstract][Full Text] [Related]
93. Cystathionine β-synthase-derived hydrogen sulfide is involved in human malignant hyperthermia. Vellecco V; Mancini A; Ianaro A; Calderone V; Attanasio C; Cantalupo A; Andria B; Savoia G; Panza E; Di Martino A; Cirino G; Bucci M Clin Sci (Lond); 2016 Jan; 130(1):35-44. PubMed ID: 26460077 [TBL] [Abstract][Full Text] [Related]
94. On the nature of the link between malignant hyperthermia and exertional heatstroke. Bourdon L; Canini F Med Hypotheses; 1995 Sep; 45(3):268-70. PubMed ID: 8569550 [TBL] [Abstract][Full Text] [Related]
95. 4-chloro-m-cresol cannot detect malignant hyperthermia equivocal cells in an alternative minimally invasive diagnostic test of malignant hyperthermia susceptibility. Weigl LG; Ludwig-Papst C; Kress HG Anesth Analg; 2004 Jul; 99(1):103-107. PubMed ID: 15281512 [TBL] [Abstract][Full Text] [Related]
96. [Effects of serotonin 2 receptor agonists on skeletal muscle preparations in patients with a disposition toward malignant hyperthermia]. Wappler F; Roewer N; Köchling A; Scholz J; Steinfath M; Rumberger E; Löscher W; Schulte am Esch J Anaesthesist; 1995 Aug; 44(8):538-44. PubMed ID: 7573901 [TBL] [Abstract][Full Text] [Related]
97. Effects of the phosphodiesterase-III inhibitor enoximone on skeletal muscle specimens from malignant hyperthermia susceptible patients. Fiege M; Wappler F; Scholz J; Weisshorn R; von Richthofen V; Schulte am Esch J J Clin Anesth; 2000 Mar; 12(2):123-8. PubMed ID: 10818326 [TBL] [Abstract][Full Text] [Related]
98. Chlorocresol, an additive to commercial succinylcholine, induces contracture of human malignant hyperthermia-susceptible muscles via activation of the ryanodine receptor Ca2+ channel. Tegazzin V; Scutari E; Treves S; Zorzato F Anesthesiology; 1996 Jun; 84(6):1380-5. PubMed ID: 8669679 [TBL] [Abstract][Full Text] [Related]
100. Mutations in the RYR1 gene in Italian patients at risk for malignant hyperthermia: evidence for a cluster of novel mutations in the C-terminal region. Galli L; Orrico A; Cozzolino S; Pietrini V; Tegazzin V; Sorrentino V Cell Calcium; 2002 Sep; 32(3):143-51. PubMed ID: 12208234 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]